• Revenue up 5.4% and Group EBITDA up 171% from Continuing Operations
• Delivered a return to profitability alongside positive EBITDA from continuing operations
• Embedded Health Solutions (EHS) underlying EBITDA up 13% over prior corresponding period

Careteq Limited (ASX: CTQ), a clinical healthtech company specialising in innovative medication management and clinical governance solutions, has released its unaudited preliminary full year results for the period ended 30 June 2025 ('FY25'). The Company reported a group EBITDA profit from continuing operations of $0.3 million, compared to a loss of $1.4 million in the prior corresponding period. Group revenues for continuing operations were up 5.4% over the prior corresponding period to $7.6 million, and underlying group EBITDA from continuing operations, which excludes one-off expenditure, was up 171% over the prior corresponding period to $0.5 million. The Company's Embedded Health Solutions (EHS) business unit also saw its underlying EBITDA increase by 13% over the prior corresponding period to $1.7 million. The strategic decisions made at the beginning of FY25, including the divestment of the loss-making Sofihub business and the acquisition of the remaining 45% of EHS, have streamlined the business and allowed it to focus on its core medication management and clinical governance offerings. The Company expects to continue to deliver revenue growth and positive EBITDA/NPAT from its continuing operations in FY26.

Careteq expects full year operational revenue and EBITDA growth from continued operations in FY26.

The Company will continue to balance managing its business operations to drive continued profitability across its Embedded Health Solutions and HMR Referrals platforms whilst working with its legal advisors and the ATO to resolve the R&D Incentive dispute.